m6A Target Gene Information
General Information of the m6A Target Gene (ID: M6ATAR00327)
Full List of m6A Methylation Regulator of This Target Gene and Corresponding Disease/Drug Response(s)
MAPK1
can be regulated by the following regulator(s), and cause disease/drug response(s). You can browse detail information of regulator(s) or disease/drug response(s).
Browse Regulator
Browse Disease
Browse Drug
Heterogeneous nuclear ribonucleoproteins A2/B1 (HNRNPA2B1) [READER]
In total 3 item(s) under this regulator | ||||
Experiment 1 Reporting the m6A Methylation Regulator of This Target Gene | [1] | |||
Response Summary | hnRNPA2B1 promotes colon cancer progression via the MAPK pathway. hnRNPA2B1 is an upstream regulator of the ERK/Mitogen-activated protein kinase 1 (MAPK/ERK2/MAPK1) pathway and inhibition of MAPK signaling blocked the effects of hnRNPA2B1. | |||
Target Regulation | Up regulation | |||
Responsed Disease | Colon cancer | ICD-11: 2B90 | ||
Pathway Response | MAPK signaling | hsa04010 | ||
Cell Process | Arrest cell cycle at G0/G1 phase | |||
Cell apoptosis | ||||
In-vitro Model | HCT 116 | Colon carcinoma | Homo sapiens | CVCL_0291 |
SW480 | Colon adenocarcinoma | Homo sapiens | CVCL_0546 | |
In-vivo Model | Four-week-old male BALB/c nude mice (purchased from Lingchang company) were randomly divided into three groups, each group has five mice. Each of the mice was injected subcutaneously on the right lateral back with 1 × 106 of each lentivirus infected SW480 cells in which hnRNPA2B1 was knocked out or negative control cells. Mice were killed at day 29, and tumors were then isolated, photographed. | |||
Experiment 2 Reporting the m6A Methylation Regulator of This Target Gene | [2] | |||
Response Summary | In breast cancer, modest stable overexpression of A2B1 in MCF-7 cells (MCF-7-A2B1 cells) resulted in tamoxifen and fulvestrant- resistance whereas knockdown of A2B1 in LCC9 and LY2 cells restored tamoxifen and fulvestrant, endocrine-sensitivity. MCF-7-A2B1 cells have increased ER-alpha and reduced miR-222-3p that targets ER-alpha. MCF-7-A2B1 have activated AKT and Mitogen-activated protein kinase 1 (MAPK/ERK2/MAPK1) that depend on A2B1 expression and are growth inhibited by inhibitors of these pathways. | |||
Target Regulation | Up regulation | |||
Responsed Disease | Breast cancer | ICD-11: 2C60 | ||
Responsed Drug | Fulvestrant | Approved | ||
Pathway Response | MAPK signaling pathway | hsa04010 | ||
PI3K-Akt signaling pathway | hsa04151 | |||
Cell Process | Cell migration and invasion | |||
In-vitro Model | HCC1806 | Breast squamous cell carcinoma | Homo sapiens | CVCL_1258 |
MCF-7 | Invasive breast carcinoma | Homo sapiens | CVCL_0031 | |
MDA-MB-231 | Breast adenocarcinoma | Homo sapiens | CVCL_0062 | |
MDA-MB-468 | Breast adenocarcinoma | Homo sapiens | CVCL_0419 | |
T-47D | Invasive breast carcinoma | Homo sapiens | CVCL_0553 | |
Experiment 3 Reporting the m6A Methylation Regulator of This Target Gene | [2] | |||
Response Summary | In breast cancer, modest stable overexpression of A2B1 in MCF-7 cells (MCF-7-A2B1 cells) resulted in tamoxifen and fulvestrant - resistance whereas knockdown of A2B1 in LCC9 and LY2 cells restored tamoxifen and fulvestrant, endocrine-sensitivity. MCF-7-A2B1 cells have increased ER-alpha and reduced miR-222-3p that targets ER-alpha. MCF-7-A2B1 have activated AKT and Mitogen-activated protein kinase 1 (MAPK/ERK2/MAPK1) that depend on A2B1 expression and are growth inhibited by inhibitors of these pathways. | |||
Target Regulation | Up regulation | |||
Responsed Disease | Breast cancer | ICD-11: 2C60 | ||
Responsed Drug | Tamoxifen | Approved | ||
Pathway Response | MAPK signaling pathway | hsa04010 | ||
PI3K-Akt signaling pathway | hsa04151 | |||
Cell Process | Cell migration and invasion | |||
In-vitro Model | HCC1806 | Breast squamous cell carcinoma | Homo sapiens | CVCL_1258 |
MCF-7 | Invasive breast carcinoma | Homo sapiens | CVCL_0031 | |
MDA-MB-231 | Breast adenocarcinoma | Homo sapiens | CVCL_0062 | |
MDA-MB-468 | Breast adenocarcinoma | Homo sapiens | CVCL_0419 | |
T-47D | Invasive breast carcinoma | Homo sapiens | CVCL_0553 | |
Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) [READER]
In total 1 item(s) under this regulator | ||||
Experiment 1 Reporting the m6A Methylation Regulator of This Target Gene | [3] | |||
Response Summary | N6-methyladenosine (m6A) methylation modification is implicated in the pathogenesis of lung ischemia-reperfusion injury. YTHDF3 or IGF2BP2 knockdown inhibited hypoxia/reoxygenation-activated p38, Mitogen-activated protein kinase 1 (MAPK/ERK2/MAPK1), AKT, and NF-Kappa-B pathways in BEAS-2B cells, and inhibited p-p65, IL-1-beta and TNF-alpha secretion. | |||
Target Regulation | Up regulation | |||
Responsed Disease | Gangrene or necrosis of lung | ICD-11: CA43 | ||
Pathway Response | MAPK signaling pathway | hsa04010 | ||
PI3K-Akt signaling pathway | hsa04151 | |||
Apoptosis | hsa04210 | |||
Cell Process | Biological regulation | |||
Cell apoptosis | ||||
In-vitro Model | BEAS-2B | Normal | Homo sapiens | CVCL_0168 |
In-vivo Model | After being anesthetized with urethane (i.p.), SD rats were endotracheally intubated and ventilated using an animal ventilator under the conditions: respiratory rate of 70 breaths/min, tidal volume of 20 ml/kg, and inspiratory/expiratory ratio of 1:1. | |||
YTH domain-containing family protein 3 (YTHDF3) [READER]
In total 1 item(s) under this regulator | ||||
Experiment 1 Reporting the m6A Methylation Regulator of This Target Gene | [3] | |||
Response Summary | N6-methyladenosine (m6A) methylation modification is implicated in the pathogenesis of lung ischemia-reperfusion injury. YTHDF3 or IGF2BP2 knockdown inhibited hypoxia/reoxygenation-activated p38, Mitogen-activated protein kinase 1 (MAPK/ERK2/MAPK1), AKT, and NF-Kappa-B pathways in BEAS-2B cells, and inhibited p-p65, IL-1-beta and TNF-alpha secretion. | |||
Target Regulation | Up regulation | |||
Responsed Disease | Gangrene or necrosis of lung | ICD-11: CA43 | ||
Pathway Response | MAPK signaling pathway | hsa04010 | ||
PI3K-Akt signaling pathway | hsa04151 | |||
Apoptosis | hsa04210 | |||
Cell Process | Biological regulation | |||
Cell apoptosis | ||||
In-vitro Model | BEAS-2B | Normal | Homo sapiens | CVCL_0168 |
In-vivo Model | After being anesthetized with urethane (i.p.), SD rats were endotracheally intubated and ventilated using an animal ventilator under the conditions: respiratory rate of 70 breaths/min, tidal volume of 20 ml/kg, and inspiratory/expiratory ratio of 1:1. | |||
Colon cancer [ICD-11: 2B90]
In total 1 item(s) under this disease | ||||
Experiment 1 Reporting the m6A-centered Disease Response | [1] | |||
Response Summary | hnRNPA2B1 promotes colon cancer progression via the MAPK pathway. hnRNPA2B1 is an upstream regulator of the ERK/Mitogen-activated protein kinase 1 (MAPK/ERK2/MAPK1) pathway and inhibition of MAPK signaling blocked the effects of hnRNPA2B1. | |||
Responsed Disease | Colon cancer [ICD-11: 2B90] | |||
Target Regulator | Heterogeneous nuclear ribonucleoproteins A2/B1 (HNRNPA2B1) | READER | ||
Target Regulation | Up regulation | |||
Pathway Response | MAPK signaling | hsa04010 | ||
Cell Process | Arrest cell cycle at G0/G1 phase | |||
Cell apoptosis | ||||
In-vitro Model | HCT 116 | Colon carcinoma | Homo sapiens | CVCL_0291 |
SW480 | Colon adenocarcinoma | Homo sapiens | CVCL_0546 | |
In-vivo Model | Four-week-old male BALB/c nude mice (purchased from Lingchang company) were randomly divided into three groups, each group has five mice. Each of the mice was injected subcutaneously on the right lateral back with 1 × 106 of each lentivirus infected SW480 cells in which hnRNPA2B1 was knocked out or negative control cells. Mice were killed at day 29, and tumors were then isolated, photographed. | |||
Colorectal cancer [ICD-11: 2B91]
Breast cancer [ICD-11: 2C60]
In total 2 item(s) under this disease | ||||
Experiment 1 Reporting the m6A-centered Disease Response | [2] | |||
Response Summary | In breast cancer, modest stable overexpression of A2B1 in MCF-7 cells (MCF-7-A2B1 cells) resulted in tamoxifen and fulvestrant- resistance whereas knockdown of A2B1 in LCC9 and LY2 cells restored tamoxifen and fulvestrant, endocrine-sensitivity. MCF-7-A2B1 cells have increased ER-alpha and reduced miR-222-3p that targets ER-alpha. MCF-7-A2B1 have activated AKT and Mitogen-activated protein kinase 1 (MAPK/ERK2/MAPK1) that depend on A2B1 expression and are growth inhibited by inhibitors of these pathways. | |||
Responsed Disease | Breast cancer [ICD-11: 2C60] | |||
Target Regulator | Heterogeneous nuclear ribonucleoproteins A2/B1 (HNRNPA2B1) | READER | ||
Target Regulation | Up regulation | |||
Responsed Drug | Fulvestrant | Approved | ||
Pathway Response | MAPK signaling pathway | hsa04010 | ||
PI3K-Akt signaling pathway | hsa04151 | |||
Cell Process | Cell migration and invasion | |||
In-vitro Model | HCC1806 | Breast squamous cell carcinoma | Homo sapiens | CVCL_1258 |
MCF-7 | Invasive breast carcinoma | Homo sapiens | CVCL_0031 | |
MDA-MB-231 | Breast adenocarcinoma | Homo sapiens | CVCL_0062 | |
MDA-MB-468 | Breast adenocarcinoma | Homo sapiens | CVCL_0419 | |
T-47D | Invasive breast carcinoma | Homo sapiens | CVCL_0553 | |
Experiment 2 Reporting the m6A-centered Disease Response | [2] | |||
Response Summary | In breast cancer, modest stable overexpression of A2B1 in MCF-7 cells (MCF-7-A2B1 cells) resulted in tamoxifen and fulvestrant - resistance whereas knockdown of A2B1 in LCC9 and LY2 cells restored tamoxifen and fulvestrant, endocrine-sensitivity. MCF-7-A2B1 cells have increased ER-alpha and reduced miR-222-3p that targets ER-alpha. MCF-7-A2B1 have activated AKT and Mitogen-activated protein kinase 1 (MAPK/ERK2/MAPK1) that depend on A2B1 expression and are growth inhibited by inhibitors of these pathways. | |||
Responsed Disease | Breast cancer [ICD-11: 2C60] | |||
Target Regulator | Heterogeneous nuclear ribonucleoproteins A2/B1 (HNRNPA2B1) | READER | ||
Target Regulation | Up regulation | |||
Responsed Drug | Tamoxifen | Approved | ||
Pathway Response | MAPK signaling pathway | hsa04010 | ||
PI3K-Akt signaling pathway | hsa04151 | |||
Cell Process | Cell migration and invasion | |||
In-vitro Model | HCC1806 | Breast squamous cell carcinoma | Homo sapiens | CVCL_1258 |
MCF-7 | Invasive breast carcinoma | Homo sapiens | CVCL_0031 | |
MDA-MB-231 | Breast adenocarcinoma | Homo sapiens | CVCL_0062 | |
MDA-MB-468 | Breast adenocarcinoma | Homo sapiens | CVCL_0419 | |
T-47D | Invasive breast carcinoma | Homo sapiens | CVCL_0553 | |
Gangrene or necrosis of lung [ICD-11: CA43]
In total 2 item(s) under this disease | ||||
Experiment 1 Reporting the m6A-centered Disease Response | [3] | |||
Response Summary | N6-methyladenosine (m6A) methylation modification is implicated in the pathogenesis of lung ischemia-reperfusion injury. YTHDF3 or IGF2BP2 knockdown inhibited hypoxia/reoxygenation-activated p38, Mitogen-activated protein kinase 1 (MAPK/ERK2/MAPK1), AKT, and NF-Kappa-B pathways in BEAS-2B cells, and inhibited p-p65, IL-1-beta and TNF-alpha secretion. | |||
Responsed Disease | Gangrene or necrosis of lung [ICD-11: CA43] | |||
Target Regulator | Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) | READER | ||
Target Regulation | Up regulation | |||
Pathway Response | MAPK signaling pathway | hsa04010 | ||
PI3K-Akt signaling pathway | hsa04151 | |||
Apoptosis | hsa04210 | |||
Cell Process | Biological regulation | |||
Cell apoptosis | ||||
In-vitro Model | BEAS-2B | Normal | Homo sapiens | CVCL_0168 |
In-vivo Model | After being anesthetized with urethane (i.p.), SD rats were endotracheally intubated and ventilated using an animal ventilator under the conditions: respiratory rate of 70 breaths/min, tidal volume of 20 ml/kg, and inspiratory/expiratory ratio of 1:1. | |||
Experiment 2 Reporting the m6A-centered Disease Response | [3] | |||
Response Summary | N6-methyladenosine (m6A) methylation modification is implicated in the pathogenesis of lung ischemia-reperfusion injury. YTHDF3 or IGF2BP2 knockdown inhibited hypoxia/reoxygenation-activated p38, Mitogen-activated protein kinase 1 (MAPK/ERK2/MAPK1), AKT, and NF-Kappa-B pathways in BEAS-2B cells, and inhibited p-p65, IL-1-beta and TNF-alpha secretion. | |||
Responsed Disease | Gangrene or necrosis of lung [ICD-11: CA43] | |||
Target Regulator | YTH domain-containing family protein 3 (YTHDF3) | READER | ||
Target Regulation | Up regulation | |||
Pathway Response | MAPK signaling pathway | hsa04010 | ||
PI3K-Akt signaling pathway | hsa04151 | |||
Apoptosis | hsa04210 | |||
Cell Process | Biological regulation | |||
Cell apoptosis | ||||
In-vitro Model | BEAS-2B | Normal | Homo sapiens | CVCL_0168 |
In-vivo Model | After being anesthetized with urethane (i.p.), SD rats were endotracheally intubated and ventilated using an animal ventilator under the conditions: respiratory rate of 70 breaths/min, tidal volume of 20 ml/kg, and inspiratory/expiratory ratio of 1:1. | |||
Fulvestrant
[Approved]
In total 1 item(s) under this drug | ||||
Experiment 1 Reporting the m6A-centered Drug Response | [2] | |||
Response Summary | In breast cancer, modest stable overexpression of A2B1 in MCF-7 cells (MCF-7-A2B1 cells) resulted in tamoxifen and fulvestrant- resistance whereas knockdown of A2B1 in LCC9 and LY2 cells restored tamoxifen and fulvestrant, endocrine-sensitivity. MCF-7-A2B1 cells have increased ER-alpha and reduced miR-222-3p that targets ER-alpha. MCF-7-A2B1 have activated AKT and Mitogen-activated protein kinase 1 (MAPK/ERK2/MAPK1) that depend on A2B1 expression and are growth inhibited by inhibitors of these pathways. | |||
Target Regulator | Heterogeneous nuclear ribonucleoproteins A2/B1 (HNRNPA2B1) | READER | ||
Target Regulation | Up regulation | |||
Responsed Disease | Breast cancer | ICD-11: 2C60 | ||
Pathway Response | MAPK signaling pathway | hsa04010 | ||
PI3K-Akt signaling pathway | hsa04151 | |||
Cell Process | Cell migration and invasion | |||
In-vitro Model | HCC1806 | Breast squamous cell carcinoma | Homo sapiens | CVCL_1258 |
MCF-7 | Invasive breast carcinoma | Homo sapiens | CVCL_0031 | |
MDA-MB-231 | Breast adenocarcinoma | Homo sapiens | CVCL_0062 | |
MDA-MB-468 | Breast adenocarcinoma | Homo sapiens | CVCL_0419 | |
T-47D | Invasive breast carcinoma | Homo sapiens | CVCL_0553 | |
Tamoxifen
[Approved]
In total 1 item(s) under this drug | ||||
Experiment 1 Reporting the m6A-centered Drug Response | [2] | |||
Response Summary | In breast cancer, modest stable overexpression of A2B1 in MCF-7 cells (MCF-7-A2B1 cells) resulted in tamoxifen and fulvestrant - resistance whereas knockdown of A2B1 in LCC9 and LY2 cells restored tamoxifen and fulvestrant, endocrine-sensitivity. MCF-7-A2B1 cells have increased ER-alpha and reduced miR-222-3p that targets ER-alpha. MCF-7-A2B1 have activated AKT and Mitogen-activated protein kinase 1 (MAPK/ERK2/MAPK1) that depend on A2B1 expression and are growth inhibited by inhibitors of these pathways. | |||
Target Regulator | Heterogeneous nuclear ribonucleoproteins A2/B1 (HNRNPA2B1) | READER | ||
Target Regulation | Up regulation | |||
Responsed Disease | Breast cancer | ICD-11: 2C60 | ||
Pathway Response | MAPK signaling pathway | hsa04010 | ||
PI3K-Akt signaling pathway | hsa04151 | |||
Cell Process | Cell migration and invasion | |||
In-vitro Model | HCC1806 | Breast squamous cell carcinoma | Homo sapiens | CVCL_1258 |
MCF-7 | Invasive breast carcinoma | Homo sapiens | CVCL_0031 | |
MDA-MB-231 | Breast adenocarcinoma | Homo sapiens | CVCL_0062 | |
MDA-MB-468 | Breast adenocarcinoma | Homo sapiens | CVCL_0419 | |
T-47D | Invasive breast carcinoma | Homo sapiens | CVCL_0553 | |
References